Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01421368
Other study ID # A10-114
Secondary ID
Status Completed
Phase Phase 1
First received August 9, 2011
Last updated April 9, 2015
Start date March 2012
Est. completion date March 2014

Study information

Verified date April 2015
Source CONRAD
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationDominican Republic: Consejo Nacional de Bioetica en Salud
Study type Interventional

Clinical Trial Summary

The purpose of the study is to examine the effects of two contraceptive methods and the menstrual cycle on the pharmacokinetics, pharmacodynamics of tenofovir 1% gel and the effect of the contraceptive methods on markers of mucosal safety.


Description:

Each woman will be seen in 6 visits and will be contacted by two scheduled follow-up telephone calls/visits. Volunteers will be consented at Visit 1 and undergo procedures to assess whether they are eligible to continue in the study. At Visit 2 (cycle days 20-25), after it has been confirmed that the participant meets all of the inclusion criteria and none of the exclusion criteria, genital samples will be taken and she will be given 2 applicators of tenofovir 1% gel to insert two hours apart. She will be instructed to return for Visit 3, approximately 3 or 11 hours after insertion of the second gel, as determined by randomization. The participant will retain this sampling assignment throughout the study.

At Visit 3 (cycle days 20-25), blood and genital samples will be collected. The participant will again be given 2 applicators of tenofovir 1% gel to insert two hours apart. She will be instructed to return approximately 3 or 11 hours after insertion of the second gel for Visit 4 (cycle days 5-10) and blood and genital samples will be taken. The participant will then start the contraceptive method that she has chosen from the two methods being evaluated in the study.

Each participant will be contacted about 4-5 weeks after Visit 4 to confirm the next visit date (Visit 5).

Visit 5 will take place about 6 weeks after starting contraception and will not have an associated gel use. Follow-up genital samples will be collected at Visit 5. The participant will be given 2 applicators of tenofovir 1% gel to insert two hours apart prior to Visit 6.

Visit 6 will take place about 10 weeks after starting contraception. Follow-up blood and genital samples will be collected approximately 3 or 11 hours after insertion of the second gel.

Each participant also will have a follow-up call or visit approximately 1-2 weeks after Visit 6 to confirm that there have been no adverse experiences. If necessary, she may be seen in an unscheduled visit for follow-up. She will then be exited from the study.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Willing and able to use OCs or DMPA

- General good health (by volunteer history and investigator assessment) without any clinically significant systemic disease

- Currently having regular menstrual cycles of 25 to 35 days by volunteer report

- History of Pap smears and follow-up consistent with American Congress of Obstetricians and Gynecologists (ACOG) practice bulletin #99 or #109 or willing to undergo a Pap smear at Visit 1

- Willing to follow protocol requirements including abstinence, use of study condoms, and prohibited use of intravaginal products

- Willing to follow post-biopsy restrictions for at least 5 days following genital biopsies

- Meets one of the following criteria:

1. Sexually abstinent and planning to remain abstinent for the duration of the study.

2. In a mutually monogamous relationship for at least the last 4 months with a male partner who is at least 18 years of age, willing to use condoms, and has no known HIV infection or risks for sexually transmitted infections (STIs)

3. In a mutually monogamous same-sex relationship for at least the last 4 months with a partner who is at least 18 years of age and has no known HIV infection or risks for STIs

- Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy genital tract sample collection

- Negative urine pregnancy test

- Willing to give voluntary consent, sign an informed consent form and comply with study procedures, as required by the protocol

Exclusion Criteria:

- History of hysterectomy

- Currently pregnant or within 2 calendar months from the last pregnancy outcome. (Note: If recently pregnant must have had at least 2 spontaneous menses since pregnancy outcome.)

- Use of any hormonal contraceptive method in the last 30 days (oral, transdermal, transvaginal, implant, or hormonal intrauterine contraceptive device)

- Injection of DMPA in the last 6 months

- Protection from pregnancy by presence of a copper IUD

- Currently breastfeeding or having breastfed an infant in the last 2 months, or planning to breastfeed during the course of the study

- History of sensitivity/allergy to any component of the study product, or topical anesthetic, or allergy to both silver nitrate and Monsel's solution

- Diagnosed with or treated for any STI or pelvic inflammatory disease in the last 6 months. (Note: Women with a history of genital herpes or condylomata who have been asymptomatic for at least 6 months may be considered for eligibility.)

- Positive test for Trichomonas vaginalis, Neisseria gonorrhoeae or Chlamydia trachomatis

- Symptomatic vulvovaginal candidiasis, Nugent score greater than or equal to 7 at screening or bacterial vaginosis (BV) at Visit 2, or urinary tract infection (UTI)

- Deep epithelial genital findings such as abrasions, ulcerations, or lacerations, or vesicles suspicious for STIs

- Positive test for HIV

- Positive test for Hepatitis B surface antigen (HBsAg)

- Known bleeding disorder that could lead to prolonged or continuous bleeding with biopsy

- Chronic or acute vulvar or vaginal symptoms (e.g., pain, irritation, or spotting)

- Contraindications to the chosen contraceptive method

- Known current drug or alcohol abuse which could impact study compliance

- Grade 1 or higher laboratory abnormality, per the August 2009 update of the DAIDS Table for Grading the Severity of Adverse Events

- Participation in any other investigational trial (device, drug, or vaginal trial) in the last 30 days or planned participation in any other investigational trial during the study

- History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix in the last 14 days

- Abnormal finding on laboratory or physical examination or a social or medical condition which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data

- Systemic use in the last two weeks or anticipated use during the study of any of the following: corticosteroids, antibiotics, antifungals, antivirals or antiretrovirals

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Tenofovir 1% vaginal gel
Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
Depo-medroxyprogesterone acetate (DMPA)
DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
Oral contraceptive: LNG 150 mcg and EE 30 mcg
Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills

Locations

Country Name City State
Dominican Republic Profamilia Santo Domingo
United States Easter Virginia Medical School Norfolk Virginia
United States University of Pittsburgh School of Medicine, Center for Family Planning Research Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
CONRAD

Countries where clinical trial is conducted

United States,  Dominican Republic, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of oral contraceptives and DMPA on tenofovir PK, PD, and safety by comparing the following endpoints before initiation of contraceptive method and 10 weeks after initiation of contraceptive method composite of pharmacokinetics for TFV in plasma, vaginal aspirate & genital tissue
composite of pharmacokinetics for TFV-DP in PBMCs, endocervical cells & genital tissue
rates of HIV-1 infection in an explant challenge assay (one site only)
immune cell activation & mucosal histology in genital tissue
genitourinary AEs
3 and 11 hours after insertion of 2 doses of study gel No
Secondary Effect of the menstrual cycle of the tenofovir PK, PD, and safety by comparing the following endpoints 3 and 1 hours after insertion of 2 doses of study gel, in the follicular and luteal phases before initiating contraception composite of pharmacokinetics for TFV in plasma, vaginal aspirate & genital tissue
composite of pharmacokinetics for TFV-DP in PBMCs, endocervical cells & genital tissue
rates of HIV-1 infection in an explant challenge assay (one site only)
immune cell activation & mucosal histology in genital tissue
genitourinary AEs
3 and 11 hours after insertion of 2 doses of study gel No
Secondary To assess the effect of oral contraceptives and DMPA on markers of mucosal immunity by comparing the following endpoints (in the absence of tenofovir) before initiation of contraceptive method and 10 weeks after initiation of contraceptive method soluble immune markers in the CVL supernatant
anti-HIV and anti-HSV in CVL
immune cell characterization in the CVL cell pellet
immune cell activation and mucosal histology in genital tissue
rates of HIV-1 infection in an explant challenge assay (one site only)
vaginal microflora
genitourinary AEs
Before (baseline) and 10 weeks after contraceptive method start No
See also
  Status Clinical Trial Phase
Completed NCT03411577 - Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program N/A
Active, not recruiting NCT03112369 - Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use N/A
Not yet recruiting NCT03642314 - HIV Self-testing in Implementation PrEP Study N/A
Completed NCT01810315 - Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity Phase 1
Completed NCT00984971 - Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet Phase 1
Completed NCT00142935 - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 N/A
Active, not recruiting NCT03255915 - PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) Early Phase 1
Completed NCT05037513 - Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky N/A
Recruiting NCT05087680 - An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South N/A
Recruiting NCT05804461 - Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico N/A
Completed NCT03148171 - Project WERK (Wellness Encouragement Respect Kinship) N/A
Completed NCT04791007 - OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults Early Phase 1
Recruiting NCT05412433 - Clinic-based HIV Identification and Prevention Project Using Electronic Resources N/A
Active, not recruiting NCT03977181 - The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms N/A
Recruiting NCT05165745 - Stick2PrEP Cisgender Women and Trans Individuals N/A
Completed NCT03719053 - Single Dose Truvada Study Phase 1
Recruiting NCT03856580 - Long-acting Biomedical HIV Prevention in Transgender Women N/A
Completed NCT02750540 - Optimization of a Tenofovir Enema for HIV Prevention Phase 1
Completed NCT01386294 - Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection Phase 3
Completed NCT00993811 - The Shang Ring: A Novel Male Circumcision Device for HIV Prevention Phase 1